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Scotland benefits from an integrated national healthcare team for motor neurone
disease (MND) and a tradition of rich clinical data capture using the Scottish MND
Register (launched in 1989; one of the first national registers). The Scottish register
was relaunched in 2015 as Clinical Audit Research and Evaluation of MND (CARE-
MND), an electronic platform for prospective, population-based research. We aimed to
determine if incidence of MND is changing over time.
Methods
Capture-recapture methods determined incidence of MND in 2015-16. Incidence rates
for 2015-16 and 1989-98 were direct age and sex standardised to allow time period
comparison. Phenotypic characteristics and socioeconomic status of the cohort are
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described.
Results
Coverage of the CARE-MND platform was 99%. Crude incidence in the 2015-17 period
was 3.83/100,000 person-years (95% CI 3.53-4.14). Direct age standardised incidence
in 2015 was 3.42/100,000 (95% CI 2.99-3.91); in 2016, 2.89/100,000 (95% CI 2.50-
3.34). The 1989-98 direct standardised annual incidence estimate was 2.32/100,000
(95% CI 2.26-2.37). 2015-16 standardised incidence was 66.9% higher than Northern
European estimates. Socioeconomic status was not associated with MND.
Conclusions
Our data show a changing landscape of MND in Scotland, with a rise in incidence by
36.0% over a 25-year period. This is likely attributable to ascertainment in the context
of improved neurological services in Scotland. Our data suggest that CARE-MND is a
reliable national resource and findings can be extrapolated to other Northern European
populations.
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Objectives:  Scotland benefits from an integrated national healthcare team for motor neurone disease 
(MND) and a tradition of rich clinical data capture using the Scottish MND Register (launched in 1989; 
one of the first national registers).  The Scottish register was relaunched in 2015 as Clinical Audit 
Research and Evaluation of MND (CARE-MND), an electronic platform for prospective, population-
based research.  We aimed to determine if incidence of MND is changing over time. 
Methods: Capture-recapture methods determined incidence of MND in 2015-16.  Incidence rates for 
2015-16 and 1989-98 were direct age and sex standardised to allow time period comparison.  
Phenotypic characteristics and socioeconomic status of the cohort are described.       
Results: Coverage of the CARE-MND platform was 99%.  Crude incidence in the 2015-17 period was 
3.83/100,000 person-years (95% CI 3.53-4.14).  Direct age standardised incidence in 2015 was 
3.42/100,000 (95% CI 2.99-3.91); in 2016, 2.89/100,000 (95% CI 2.50-3.34).  The 1989-98 direct 
standardised annual incidence estimate was 2.32/100,000 (95% CI 2.26-2.37).  2015-16 standardised 
incidence was 66.9% higher than Northern European estimates.  Socioeconomic status was not 
associated with MND.       
Conclusions:  Our data show a changing landscape of MND in Scotland, with a rise in incidence by 
36.0% over a 25-year period.  This is likely attributable to ascertainment in the context of improved 
neurological services in Scotland.  Our data suggest that CARE-MND is a reliable national resource and 






































































Motor neurone disease (MND) refers to a spectrum of neurodegenerative diseases for which there 
remains no cure.  The most common manifestation is amyotrophic lateral sclerosis (ALS), which 
typically results in progressive involvement of upper and lower motor neurones.  Recent discoveries 
support a multifactorial aetiopathogenesis, with genetic and/or environmental risk factors[1,2].  
Regional variation in disease incidence could be expected, corresponding with population ancestral 
origin and environmental exposures[3].  However, a recent meta-analysis of global registry data of ALS 
and MND-subtypes observed epidemiological homogeneity amongst populations of European 
origin[4].   
Scotland benefits from a culture of longstanding MND data capture[5].  The Scottish Motor Neurone 
Disease Register (SMNDR) was established in 1989, aiming to collect data regarding incident patients 
[6].  Annual incidence of MND was 2.40 per 100,000 population (95% confidence interval (CI) 2.22-
2.58) between 1989-1998, standardised to 1994 mid-year Scottish population estimates[7].  A two 
source capture-recapture model demonstrated 97.8% national coverage[7].  SMNDR coverage 
declined between 1999 and 2014[8].  However, in 2015, the SMNDR was re-launched and modernised 
as an integrative platform, Clinical Audit Research and Evaluation of Motor Neurone Disease (CARE-
MND).  The platform facilitates electronic collection of prospective patient data.  We aimed to use 
CARE-MND to describe the epidemiology of MND in Scotland in 2015-2017, in comparison to the 1989-
1998 study period, and in the context of recent European population statistics.  Phenotypic 




Inclusion criteria were: i) diagnosed by a neurologist with possible, probable or definite ALS according 
to El Escorial revised criteria or an MND subtype (primary lateral sclerosis (PLS), progressive bulbar 
palsy (PBP), progressive muscular atrophy (PMA))[9], ii) diagnosed 2015-2017, iii) ≥16 years old at 
diagnosis, iv) resident in Scotland at time of diagnosis.   
 
Case ascertainment 
CARE-MND retrieves population data from five sources (Figure 1).   




































































The CARE-MND platform is a prospective clinical tool and all cases are monitored by neurologists and 
nurse/allied health specialists.  If a diagnosis is revised or revoked, the patient is removed from the 
database.  CARE-MND notifications are therefore considered ‘gold-standard’.  Patients are referred to 
a local MND nurse/allied health specialist, who coordinates care.  The CARE-MND electronic platform 
operates via a secure website hosted on an academic server.  MND specialists enter information about 
incident patients following referral and until death.  If a patient is diagnosed with MND shortly before, 
or after, death the relevant care provider can refer for retrospective data entry.   
Patients are invited to participate in the CARE-MND platform and can self-notify online.  A member of 
the CARE-MND team contacts the patient’s neurology consultant/clinical specialist to confirm 
diagnosis before entry onto the database.     
 
ii) ISD Data 
Information Services Division (ISD) Scotland data were extracted.  Patients were sourced if they were 
assigned International Statistical Classification of Diseases v10 (2016) (ICD-10) codes for Motor 
Neurone Disease (G12.2) or Frontotemporal Dementia (G31.0 and/or F02.0) on hospital records or as 
primary or secondary cause of death during 2015 and 2016.  Patients prescribed riluzole, a drug 
uniquely used for MND, were also included.   
 
Data Extraction and Statistical Analysis 
Related sources were collapsed, resulting in two independent sources for capture-recapture analysis 
(Figure 1).  Maximum likelihood estimates determined database coverage and total incidence rates[7].  
Prevalence was extracted directly from CARE-MND.  Rates were calculated in reference to National 
Records of Scotland (NRS) mid-population estimates[10].  Incidence rates were standardised using the 
direct method to the US 2010 Census population[11].  This population has been used historically for 
Scottish and other population standardisation[4,7].  The 2010 population was chosen to allow direct 
comparison with recent pooled incidence data[4].  Confidence intervals were calculated assuming a 
Poisson distribution.   
The CARE-MND platform provides a standardised national proforma and phenotypic fields were 
extracted (Table 2).  Individuals diagnosed in 2015-16 were followed up for at least one year; 6-month 
and 12-month survival from onset and diagnosis were examined.  Patients were mapped to their 




































































small data zones according to level of deprivation, accounting for employment, income, crime, 
housing, health, education and access to medical care/transport).  SIMD quintiles (1 most deprived, 5 
least deprived) were analysed using Dunn’s test of multiple comparisons using rank sums.  R v3.4.3 
was used for all statistical analyses[12].     
 
Ethics 
Ethical approvals were obtained for the SMNDR/CARE-MND (MREC/98/0/56 1989-2010, 
10/MRE00/78 2011-2015, Scotland A Research Ethics Committee (15/SS/0216) 2015-present).  Access 





The CARE-MND database alone identified 406 true MND cases diagnosed in 2015-16 (Table 1).  There 
were 596 prevalent patients in 2015-2016 coded with the G12.2 code in ISD datasets.  Of these, 342 
were ‘true’ incident cases (also present in CARE-MND 2015-16).  A further 262 patients were coded 
with G12.2: 21 were incident MND cases unique to ISD and were included in our analyses (Table 1); 
eight had MND but were diagnosed before 2015 and were not included.  Case-notes of the remaining 
233 patients were reviewed; none had MND.  In summary, we identified 21/596 (3.5%) people with 
MND unique to ISD and 233/596 (39.1%) patients from ISD records who were coded with an ICD-10 
MND code inaccurately.  Forty two percent (99/233) of these patients had progressive supranuclear 
palsy (PSP).  Other diagnoses included pseudobulbar palsy secondary to cerebrovascular disease or 
dementia.   
Sensitivity of ISD code G12.2 for incident patients 2015-16 was therefore 0.89 (95% CI 0.86-0.92) with 
a positive predictive value (PPV) of 0.61 (95% CI 0.57-0.65).  The specificity and negative predictive 
value were 100% and 1 respectively, as MND is rare in the general population.  Sensitivity and PPV for 
hospital records were 0.74 (95% CI 0.69-0.78) and 0.66 (95% CI 0.62-0.71) respectively; for death 
records 0.42 (95% CI 0.37-0.47) and 0.55 (95% CI 0.49-0.61); for PIS records 0.40 (95% CI 0.35-0.45) 
and 0.96 (95% CI 0.92-0.98).   





































































Year 2015 2016 
CARE-MND notifications 221 185 
Notifications unique to CARE-MND 19 45 
Notifications unique to ISD 9 12 
Notifications common to CARE-MND and ISD 202 140 
Total notifications 230 197 
Maximum Likelihood Estimate 0.8465 3.8671 
CARE-MND coverage (%) 99.6 98.1 
Mid-year population estimate 5373000 5404700 
Crude incidence (per 100,000 population) 4.28 3.64 
 
Table 1: CARE-MND Platform Case Ascertainment and Crude Incidence 2015-16 
 
 
Case-notes of the 21 patients identified through ISD alone were examined.  Sixteen (76.2%) patients 
were diagnosed shortly before death (median 3.5 days (interquartile range (IQR) 1.8-9.5)), in which 
case contact with a MND specialist might not have been made or pursued.  Site of onset for these 
patients varied: bulbar (n=6, 37.5%), limb (n=6, 37.5%), respiratory (n=3, 18.8%), weight loss (n=1 
(6.3%).  Two patients were diagnosed posthumously: one from electromyography, one on post-
mortem.  The remaining three patients were: a nursing home resident, unknown to specialist teams; 
a patient with FTD-predominant disease receiving care from other specialists; a patient with PLS who 
declined specialist input.  
Due to the excellent coverage of CARE-MND, incidence for 2017 was estimated using CARE-MND 
values alone: 192 new diagnoses, giving a crude incidence of 3.55/100,000 (3.07-4.09) (using 2016 
mid-year population estimate as 2017 not yet available).  Crude incidence over the three-year period 
was 3.83/100,000 person-years (3.53-4.14).  On 31st December 2015, 409 people were living with MND 
in Scotland according to CARE-MND/ISD figures (crude prevalence 7.61 per 100,000 (6.89-8.39)).  
Similarly, prevalence rates in 2016 and 2017 were 413 (7.64/100,000 (6.92-8.42)) and 422 
(7.81/100,000 (7.08-8.59)).   
 
Direct Standardisation 
Incidence rates for 2015 and 2016 were age and sex standardised to the US Census Population 2010 
(Supplementary Table 1).  Age-standardised incidence for 2015 was 3.42/100,000 (2.99-3.91).  Age-
standardised incidence for males was 2.00/100,000 (1.68-2.39) and for females 2.64/100,000 (2.12-




































































2.89/100,000 (2.50-3.34) overall; for males, 3.51/100,000 (2.90-4.24), and for females, 2.26/100,000 
(1.78-2.86) with a RR of 1.55:1.  In both years, peak age-group incidence for males was 65-69 years.  
In 2015, female peak incidence was in the 75-79 age group, but in the 60-64 age range in 2016 (Figure 
2).  Incidence rates for 1989-98 were age-standardised to allow time period comparison (Figure 3).  
Overall, age-standardised incidence for this period was 2.32/100,000 (2.26-2.37).  In 2015-16, 
incidence was greater than 1989-98 across most age groups, but particularly in the 55-74 year cohort.  
Finally, age and sex time period comparison was plotted (Figure 4), highlighting that the clearest 
change is among males age 60-69.  There was a 79-81% increase in incidence of males age 65-69 years 
in 2015-16 versus 1989-98. 
 
Patient Characteristics  
Phenotypic characteristics were evaluated from the 2015 and 2016 cohorts (Table 2).  Statistical 
comparisons were made between males and females.  Females were significantly older at onset and 
diagnosis (p<0.0016).  Significantly fewer females had onset of disease in the upper limbs (p<0.0016).  
Although there was no sex difference for respiratory-onset disease, significantly fewer females 
















































































Significance Test p-value 
Male-to-Female Relative Risk  100 1.53:1         
Mean Age of Onset (SD), years 97.7 65.3 (11.6) 63.7 (11.3) 67.6 (11.7) t-test 0.00086* 
Mean Age of Diagnosis (SD), years 100 66.8 (11.2) 65.4 (11.0) 69.0 (11.1) t-test 0.00099* 
Median Time to Diagnosis (IQR), months 97.7 
11.0 (7.0-
21.0) 
11.0 (7.0-20.0) 11.0 (7.0-23.0) 




   Chi square 0.039 
-          Amyotrophic Lateral Sclerosis 79.4 80.6 77.5 Z-test proportion 0.51 
-          MND with Frontotemporal Dementia 6.8 6.2 7.7 Z-test proportion 0.69 
-          Progressive Bulbar Palsy 4.9 2.7 8.2 Z-test proportion 0.018 
-          Progressive Muscular Atrophy 4.0 4.3 3.6 Z-test proportion 0.91 
-          Primary Lateral Sclerosis 3.3 3.5 3.0 Z-test proportion 0.98 
-          Other (bibrachial/flail limb) 1.6 2.7 0.0 Z-test proportion 0.077 
Site of Onset 
98.8 
      Chi square 0.0048 
-          Bulbar 28.2 22.7 36.7 Z-test proportion 0.0024 
-          Lower limb 28.4 28.1 28.9 Z-test proportion 0.16 
-          Upper limb 20.6 26.2 12.0 Z-test proportion 0.00072* 
-          Mixed (upper limb, lower limb, bulbar) 17.1 16.0 18.7 Z-test proportion 0.56 
-          Cognitive change 2.1 3.1 0.6 Z-test proportion 0.16 
-          Respiratory 1.7 1.6 1.8 Z-test proportion 1 
-          Other (weight loss, camptocormia) 1.9 2.3 1.2 Z-test proportion 0.64 
Ethnicity (%) 
90.6 
   Chi square 0.71 
-          White Scottish 75.2 75.1 75.3 Z-test proportion 1 
-          White British/Irish/Not Specified 23.3 23.2 23.3 Z-test proportion 1 
-          Ethnic Minority 1.3 0.9 1.3 Z-test proportion 1 
Family History (%)        
-          MND 96 8.5 5.6 12.8 Chi square 0.013 
-          Dementia 80 27.7 26.5 29.7 Chi square 0.22 




































































Gastrostomy Insertion (%) 99.5 31.5 32.0 30.8 Chi square 0.71 
Non-invasive Ventilation (%) 95.3 33.9 41.6 21.7 Chi square 3.27x10-5* 
6-Month Survival (%)        
-          From Onset 97.6 94.2 95.3 92.1 Z-test proportion 0.00039* 
-          From Diagnosis 100 70.0 74.4 62.7 Z-test proportion 0.092 
12-Month Survival (%)        
-          From Onset 97.6 70.0 85.0 80.0 Z-test proportion 0.0033 
-          From Diagnosis  100 51.3 55.8 44.4 Z-test proportion 0.0032 
 
 
Table 2: Patient characteristics and sex comparison of the 2015-2016 cohort.  Censorship date for survival = 31st December 2017.  Definition of family 




































































Scottish Index of Multiple Deprivation (SIMD) Mapping 
Patients for whom postcodes were recorded on the database (n=382) were assigned their 
corresponding SIMD rank.  Ranks ranged from 24 (most deprived) to 6953 (least deprived) (median 
3512, IQR 1964-5210).  There was an equal spread across deprivation quintiles (Dunn’s test of multiple 





We report an up-to-date, standardised epidemiological analysis of the Scottish MND population.  Case 
ascertainment methods were similar to those in the 1989-98 Scottish analysis and capture-recapture 
coverage has improved.  Case ascertainment is high for a national study, and comparable with other 
small country/regional epidemiological MND studies[13–15].   
 
Validation of ISD Coding 
With reference to the CARE-MND database, ISD records had relatively low PPVs for MND.  Death 
records were likely under-representative due to the relatively short follow-up time for this incident 
cohort (median six months, maximum 18 months).  The high predictive power of prescribing records 
is expected as riluzole is unique to the disease.  One of the main problems with coding was inaccurate 
coding of patients with PSP.  While individuals with this condition can develop a bulbar palsy similar 
to that seen in MND, their disease course and pathology is distinct.  This error has been observed 
previously and has implications for both national MND and PSP statistics[16–18]. 
  
Incidence and Prevalence 
Prevalence in 2015-17 ranged from 7.61-7.81/100,000 population.  This is comparable with recently 
published cohorts in Italy, Cyprus and the Faroe Islands[19–21].  However, it is lower than prevalence 
reported in other Italian and Dutch studies (approximately 10 per 100,000 of the 
population)[13,22,23], perhaps suggesting poorer survival in Scotland.  Future work comparing 




































































Direct standardised incidence in 2015-16 (average 3.16/100,000) has increased by 36.0% compared 
with the 1989-98 period, mirroring recent analyses of disease burden[24].  The age-standardised 
incidences of MND in Scotland for both 2015 and 2016 are the highest reported in the literature.  
Combined incidence for 2015-16 is 66.9% higher than pooled Northern European standardised 
rates[4].  Possible hypotheses for these observations include: 
 
i) Ascertainment 
Patient ascertainment may contribute to our high incidence rates.  The data suggest that no age 
groups are overlooked; older age groups are well-represented (11.9% ≥80 years at diagnosis).  This 
challenges recent discourse suggesting that MND is underdiagnosed in older populations[25]. 
Awareness of MND amongst health professionals and the public has heightened in recent years.  In 
2015, Scottish MND funding and care services were boosted through substantial government 
investment.  2016 marked a doubling of MND nurse/allied health specialists, with a specialist-to-
prevalent-patient ratio of 1:26.  Each nurse acquires approximately 12 new patients annually, 
compared with 31 patients annually 1989-1998.  Similarly, in 1989 there was one neurologist for 
approximately 231,500 people in Scotland but 1:63,500 in 2016.  New patient referrals to neurology 
rose by 50% from 2007 to 2016, suggesting better access to and more timely referral for tertiary 
review[26].  Indeed, median diagnostic delay in this study was slightly better than pooled European 
delays (11.0 months vs 12.0 months)[3].      
Concomitant with an increase in neurology service provision is better awareness of the extended 
phenotype of MND.  In comparison to 1989-98, MND-FTD is a new addition (6.8% of 2015-16 cohort).  
Such patients were previously classified as having a “MND plus” disorder[8,15,27].  Better recognition 
of the cognitive phenotype, using tools such as the Edinburgh Cognitive and Behaviour ALS Screen, 
may explain some of the change in incidence over time[28].     
 
ii) Environmental 
The rise in incidence is dominated by males age 65-69, contradicting studies suggesting older women 
drive increased incidence in aging populations[13,29].  In a Scottish analysis of patients >80 years, 
standardised incidence was greater in men suggesting a possible localised geographical effect[30].  We 
found no association between MND incidence and social deprivation (SIMD), in agreement with  
recent publications[31,32].  SIMD is a marker of residence, rather than individual exogenous variables; 




































































The change in incidence might be consequent on improved survival from competitive diseases (such 
as cardiovascular disease), allowing for increased manifestation of MND (a Gompertizian model)[29].  
Age and sex adjusted mortality from heart disease has decreased by 37.6% in Scotland over the last 
10 years[33].           
 
iii) Genetics 
Since the identification of ‘genetic’ MND, in particular SOD1 mutations and the C9orf72 
hexanucletoide repeat expansion, people with MND are increasingly undergoing genetic testing as 
part of their diagnostic work-up.  Clinicians are more aware of the phenotypic spectrum of disease of 
these mutations; for example, C9orf72 carriers can present with a pure FTD phenotype but have 
subsequent sequential motor involvement[34].  The C9orf72 expansion was first associated with MND 
in 2011 and so it is possible that these patients were missed from historical epidemiological 
cohorts[35].  The C9orf72 expansion is present in 11% of patients with MND in Scotland (familial or 
sporadic)[36,37].     
In this Scottish population, a previously published SOD1 genetic founder variant (p.I114T) is found in 
4% of all (familial and apparently sporadic) cases of MND[36,38].  We do not anticipate that the 
frequency of this mutation has changed over time but the identification of a founder mutation in this 
population may suggest the presence of other Scottish haplotypes which are driving disease.  The 
relative ethnic homogeneity of Scotland may support this hypothesis.  Genetic admixture seen in 
African American populations is thought to be protective against disease, whereas people of European 
origin are more likely to harbour homozygous and “probably damaging” genetic alleles[39].  Further 
comprehensive genetic characterisation of the Scottish population in future studies will help to 
answer this question. 
 
Phenotypic Characteristics 
In this cohort, the male-to-female ratio and mean ages of onset/diagnosis are typical[5,7,19,36].  The 
majority of patients (79.4%) had ALS, the remainder MND subtypes.  Family history of MND was higher 
in females than males although this did not reach statistical significance.  In our previous genetic 
analyses, we observed that female sex was significantly associated with having genetic MND[36].  This 
is in-keeping with a liability threshold genetic model which dictates that, in a male-dominated disease 




































































Rates of gastrostomy insertion are similar to the LIGALS population, although NIV use is lower (33.9 
vs 55.7%)[19], perhaps reflective of the relatively short follow-up period.   We observe significantly 
poorer survival of females at six months.  More females than males have bulbar-onset disease which 
might explain the drop in survival shortly after onset.  Interestingly, significantly fewer females than 
males used NIV. 
 
Limitations 
While data capture methods are similar between the 1989-98 and 2015-17 cohorts, there were key 
differences in diagnostic inclusion criteria: the historical dataset was obtained before publication of 
revised El Escorial criteria, instead relying on modified World Federation of Neurology diagnostic 
criteria for half of the cohort, and original El Escorial criteria for the remainder[41,42].  Unfortunately 
this is a limitation for many longitudinal MND population studies.    
Data collection was less comprehensive between 1999 and 2014 and our study does not allow for age-
period-cohort (APC) analysis.  Nevertheless, it gives an accurate representation of the current climate 
of MND in Scotland.  APC analysis highlights historical rather than existing potential environmental 
aetiology only.  Recent APC analysis from Ireland, a population in geographical proximity to Scotland, 
showed no birth cohort effect[43].   
Although the genetic epidemiology of the historical cohort has been studied[36], the frequency of  
rare MND-associated variants in this incident population is unknown.  Detailed genetic 
characterisation of this cohort may highlight variants that are enriched in the homogenous Scottish 
population.   
 
CONCLUSIONS 
Our study shows an increasing incidence of MND in Scotland, with the highest and most up-to-date 
standardised incidence rates reported in the literature.  We have re-established the Scottish MND 
Register (now CARE-MND platform) and can achieve 99% capture of patients.  The high ascertainment 
rates obtained from a national prospective, multi-source register imply that findings can be 
generalised to other Northern European populations.  This work and future CARE-MND analyses will 





































































Fig.1 Multiple source algorithm for accurate ascertainment of MND cases: (i) Sources related to CARE-
MND database, (ii) Sources related to Information Services Division (ISD) Scottish Government data 
Fig.2 Age and sex rates direct standardised to the 2010 US Census population for a) 2015 and b) 2016 
cohorts  
Fig.3 Time period comparison of incidence rates for i) 1989-98, ii) 2015 and iii) 2016 direct age 
standardised to the 2010 US Census population 
Fig.4 Time period comparison of incidence rates for i) 1989-98, ii) 2015 and iii) 2016 direct age and sex 
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